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ABSTRACT
Background
Treatment of asymptomatic individuals, regardless of their malaria infection status, with
regularly spaced therapeutic doses of antimalarial drugs has been proposed as a method for
reducing malaria morbidity and mortality. This strategy, called intermittent preventive
treatment (IPT), is currently employed for pregnant women and is being studied for infants
(IPTi) as well. As with any drug-based intervention strategy, it is important to understand how
implementation may affect the spread of drug-resistant parasites. This is a difficult issue to
address experimentally because of the limited size and duration of IPTi trials as well as the
intractability of distinguishing the spread of resistance due to conventional treatment of
malaria episodes versus that due to IPTi when the same drug is used in both contexts.
Methods and Findings
Using a mathematical model, we evaluated the possible impact of treating individuals with
antimalarial drugs at regular intervals regardless of their infection status. We translated
individual treatment strategies and drug pharmacokinetics into parasite population dynamic
effects and show that immunity, treatment rate, drug decay kinetics, and presumptive
treatment rate are important factors in the spread of drug-resistant parasites. Our model
predicts that partially resistant parasites are more likely to spread in low-transmission areas, but
fully resistant parasites are more likely to spread under conditions of high transmission, which is
consistent with some epidemiological observations. We were also able to distinguish between
spread of resistance due to treatment of symptomatic infections and that due to IPTi. We
showed that IPTi could accelerate the spread of resistant parasites, but this effect was only
likely to be significant in areas of low or unstable transmission.
Conclusions
The results presented here demonstrate the importance of considering both the half-life of a
drug and the existing level of resistance when choosing a drug for IPTi. Drugs to which little or
no resistance exists are not advisable for IPT in high-transmission areas, but IPTi is not likely to
significantly impact the spread of highly resistant parasites in areas where partial resistance is
already established. IPTi is more likely to accelerate the spread of resistance in high-
transmission areas than is IPT in adults (i.e., pregnant women).
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PLoS MEDICINEIntroduction
Rapidly spreading resistance to antimalarial drugs is
threatening the ability to treat malaria effectively in nearly
every malaria-endemic region of the globe. The least
expensive and safest treatment, chloroquine, has been
replaced as the ﬁrst-line drug in many countries due to
increasing prevalence of resistant parasites. Resistance to the
cheapest alternative, sulfadoxine-pyrimethamine (SP), is
threatening the viability of this treatment as well. New and
affordable pharmaceuticals are needed, but to safeguard their
usefulness as well as to extend the life of existing drugs such
as SP, the spread of drug resistance must be minimized. It is
critical to understand how patterns of drug use and the
epidemiological context of drug deployment contribute to
the emergence and spread of drug resistance in order to
protect the efﬁcacy of antimalarial drugs.
Genetic mutations that confer some level of protection
against a drug are thought to arise randomly during
replication [1]. Selection occurs when the parasites in an
infection are exposed to a drug: resistant mutants have a
survival advantage over parasites without the mutation. The
mutations can spread if gametocytes carrying the advanta-
geous mutation are transmitted to a feeding mosquito.
Typically, high-level resistance to a particular drug requires
multiple mutations that accumulate gradually over several
parasite generations. For example, increasing resistance to SP
has been correlated with the stepwise acquisition of speciﬁc
point mutations [2,3]. Parasites with different sensitivities are
able to grow at different concentrations of the drug. Fully
resistant parasites will survive a full therapeutic dose, whereas
partially resistant parasites will be selected for at intermedi-
ate concentrations that are still inhibitory for fully sensitive
parasites. The parasite-drug interaction manifests clinically
as reappearance of a detectable density of parasites within
days after treatment (partially resistant) or infections that do
not respond to treatment at all (fully resistant).
The pharmacokinetic properties of drug elimination from
the bloodstream determine the window of selection for
resistance mutations (Figure 1). Drugs with long half-lives,
such as SP, provide longer protection against infection, but
they also increase parasite exposure to subtherapeutic drug
concentrations, and thus selection for resistant mutants.
Infections that appear during the gradual decay of SP in the
bloodstream of a treated patient are more likely to be
pyrimethamine-resistant than those that appear after the
drug has cleared [4].
Drug treatment and immune mechanisms act synergisti-
cally to clear an infection. Even at permissive concentrations
of drug, antiparasite immunity can prevent resistant parasites
from proliferating [5,6]. It has been proposed that the spread
of drug resistance is driven by the greater survival and
transmission of resistant versus sensitive phenotypes during
the time between administration of the drug and immune
clearance of the infection [7]. That interval is maximized
when individuals with little or no parasite-speciﬁc immunity,
such as infants, are given antimalarial drugs.
Drug use patterns, drug pharmacokinetics, and antimalar-
ial immunity all impact the spread of drug-resistant parasites.
These three factors converge in a unique synergy in infants
undergoing intermittent preventive treatment (alternatively,
intermittent presumptive therapy), or IPT, an intervention
that involves administering antimalarial drugs to individuals
on a ﬁxed schedule, regardless of disease or infection status
[8–10]. During IPT, blood concentrations of the drug are not
maintained continuously at levels high enough to clear and
prevent infection; drug titers are expected to initially rise and
then subside between treatments. When these regular
ﬂuctuations of drug titer occur in infants, whose immunity
is not robust or speciﬁc enough to control infections, new
infections that emerge from the liver between treatments are
exposed to conditions that are ideal for selectively spreading
resistant parasites [4,11]. Moreover, because Plasmodium
blood-stage densities in infants and children are typically
orders of magnitude higher than in adolescents and adults, it
is much more likely that resistant infections will reach high
densities and increase their probability of being transmitted
[12]. In at least two trials of IPT for infants (IPTi), there were
signiﬁcant increases in the frequency of drug-resistant
infections in the treated group relative to the control group
[13,14]. The situation is exacerbated still further if infants and
children represent disproportionate reservoirs of transmis-
sion in malaria-endemic settings, as some ﬁeld studies suggest
[15–17]. Thus several lines of reasoning argue that infants and
children have a particularly signiﬁcant role in the commun-
ity-wide spread of drug-resistant parasites.
In order to understand how drug use, pharmacokinetics,
immune status, and transmission intensity may act synergisti-
cally on the spread of drug-resistant malaria, we developed a
model that combines drug use patterns with parasite ﬁtness
to predict the spread of resistance. Resistance to antimalarial
drugs is not a simple switch but requires an accumulation of
genetic changes that confer increasing levels of resistance.
Hastings et al. [11] developed one of the ﬁrst models of
antimalarial resistance that incorporated drug pharmacoki-
netics into an analysis of the spread of drug resistance; the
authors did so by allowing parasites to be either drug
sensitive, resistant to low levels of drug (partially resistant),
or resistant to full therapeutic doses (fully resistant). Their
model describes drug use as a single parameter applied
Figure 1. Pharmacokinetics of Drug Resistance
Concentration of drug in the bloodstream declines over time and falls
below threshold levels permissive for growth of parasites with varying
degreesofresistance.DashedlinesrepresentpermissivethresholdsforRS,
R1, and R2 parasites. Adapted from Hastings et al. [11]. RS, drug-sensitive
parasites; R1, partially resistant parasites; R2, fully resistant parasites.
DOI: 10.1371/journal.pmed.0030141.g001
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IPT and Drug Resistanceuniformly to a homogenous population, leaving aside trans-
mission intensity and immunity. Here we develop explicit
relationships between transmission intensity, immunity, and
drug policy in an epidemiological model that allows these
complicated and interdependent factors to be included
simultaneously, but evaluated independently.
Methods
Our analysis of the spread of drug-resistant parasites uses a
composite model of human disease and treatment and
parasite ﬁtness. The human population model tracks the
total dosing with antimalarial drugs, considering infection,
treatment, temporary immunity to reinfection, and the
development of immunity after previous exposure to
infection. The parasite population model determines which
potential hosts are available for infection by parasites with
different levels of drug sensitivity.
Human Dosing Model
Immunity to malaria develops slowly, after repeated
infection [18], and can affect the emergence and spread of
drug resistance. To model immunity, we have adapted the
Garki model [19], in which individuals who acquire some
immunity graduate to a set of compartments for infection
status and treatment that parallels those who lack it.
Individuals are born nonimmune and experience a cycle of
infection, treatment or clearance of parasites, and short-lived
immunity immediately following an episode, until graduating
to a semi-immune state. Semi-immune individuals experience
the same cycle, but with a higher probability of carrying an
asymptomatic infection and a longer interval between each
infection. The graduation from nonimmune to semi-immune
depends, at least in part, on the number of attacks, and thus
on the frequency of infectious bites. Intervention strategies,
such as chemoprophylaxis and IPTi, may be applied differ-
entially to different age groups (or, here, groups with
different immune status).
Speciﬁcally, infants are born susceptible (compartment S)
to malaria infection at a constant rate (l), and there is a
constant death rate from each compartment (lX, where X ¼
S, A, P, and the other compartments [Table 1]). The rate at
which infectious mosquitoes bite humans is known as the
entomological inoculation rate (K). A fraction (k) of suscep-
tible nonimmunes who are bitten will become symptomatic
and have a probability (p) of being treated. Symptomatic
treated individuals are designated by D. The remaining
infected individuals are untreated, designated by A, and
include those who are asymptomatic as well as those with
symptomatic infections that will go untreated. Some of the
untreated individuals will later become symptomatic, either
by receiving a new infectious bite (dK) or due to other
precipitating factors (m), and have a probability (p) of being
treated. In the treated, symptomatic individuals (D), the
waiting time between the onset of symptoms and the time
when the drug titer becomes high enough to clear the
infection is 1/a d, at which point they enter a new class T1.
Over a period of 1/r1 d, which is determined by the
pharmacokinetic properties of the drug, the drug concen-
tration declines to a level permissive to partially resistant
parasites (T19). The drug concentration falls to zero over an
additional period of 1/r2 d. After a treated clinical attack,
antimalarial immunity (P) develops and provides protection
from a new infection for 1/w d. Thus, the concentration of
drug in the blood following treatment declines as a stepwise
process until all of the drug is cleared (D ! T1 ! T19 ! P).
Untreated asymptomatic and symptomatic infections (A) are
either cleared quickly and spontaneously with no subsequent
protection (r) or they are cleared more slowly by immune
mechanisms (g) resulting in protection from reinfection (P)
for 1/w d.
Susceptible, nonimmune individuals (S), those with un-
treated infections (A), and those with immune protection (P)
may undergo periodic drug dosing during IPTi at a rate, c,
and they progress through a stepwise decay of blood drug
concentration similar to those treated for symptoms. A dose
of antimalarial drug during IPTi clears any existing,
asymptomatic, drug-sensitive infection and prevents reinfec-
tion by partially or fully sensitive parasites for a period of 1/r1
d. Between 1/r1 and 1/r1þ1/r2 d, the drug concentration drops
to a level that is still active against fully sensitive parasites, but
is permissive for infection by partially resistant parasites (i.e.,
Table 1. Compartments of Human Dosing Model Categorized by Treatment, Infection, and Immune Status
Description State Proportion of Individuals in Each State
Low Transmission High Transmission
Uninfected and untreated S 33.2% 0.03%
Sa 2.7% 0.2%
Infected but untreated A 3.1% 0.1%
Aa 0.3% 2.6%
Immune-protected and uninfected P 7.6% 0.5%
Pa 9.9% 85.8%
Infected and treated D 0.8% 0.1%
Da 0.09% 0.8%
Infected prior to treatment with drug in bloodstream T1 8.9% 1.2%
T3 2.7% 0.1%
Uninfected prior to treatment with drug in bloodstream Ta 1.0% 8.5%
T2 29.7% 0.03%
Equilibrium values of the proportion of individuals in each compartment are given for high- and low-transmission conditions. The parameter values given in Table 2 were used to reach these proportions. The prime
designations were eliminated for clarity, thus the values for T1,T 2,T 3, and Ta represent the sum of T1 and T19,T 2 and T29,T 3 and T39,T a and Ta9, respectively.
DOI: 10.1371/journal.pmed.0030141.t001
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IPT and Drug ResistanceTx ! Tx9, where x ¼ 1, 2, 3, a). Susceptible nonimmunes (S)
become treated nonimmunes (T2) after a dose of drug during
IPTi, then decay to a level of lower protection (T29), and then
return to the susceptible class (S ! T2 ! T29 ! S). Those with
untreated infections (A) who are treated through IPTi (T3)
become partially protected (T39), and have a probability (b) of
acquiring immune protection as a result of the infection (A
! T3 ! T39 ! So rA! T3 ! T39 ! P). Immune-protected
individuals (P) may also be treated through IPTi, but IPTi
does not affect the development or loss of immunity. We
assume that nonimmunes who arrive for IPT treatments with
clinical symptoms of malaria are diagnosed and treated (D).
Semi-immune status is acquired with some probability after
clearing an infection, at a rate that is proportional to
entomological inoculation rate (EIR) (cK).I m m u n i t yt o
reinfection (Pa) persists for a period of 1/w9 d, after which
susceptibility (Sa) to infection returns. A greater proportion
(1   k9) of those who are infected maintain an asymptomatic
infection or develop symptoms but go untreated (Aa), but a
small fraction (k9) become ill and have a probability (p) of
being treated (Da) with an antimalarial drug. Treatment leads
to parasite clearance and a gradual decline of drug titers, as
described above (Ta ! Ta9). Asymptomatic, infected individ-
uals may become ill for various reasons (m9), but not due to
superinfection, and have a probability (p) of being treated for
malaria.
A summary of the compartments with respect to their
disease and treatment status can be found in Table 1, along
with the equilibrium values of the proportion of individuals
in each state at any given time. The equations describing
disease and drug dosing in the human host are in Text S1.
Model of Parasite Fitness
The impact of infection and treatment described above on
the spread of resistance in these models can be measured by
determining how effectively parasites with different levels of
resistance compete under different drug usage scenarios. To
do this, we determined the relative ﬁtness of different
parasite populations, building on the concepts developed by
Hastings et al. [11]. The ﬁtness of one parasite population
relative to another is directly proportional to the ratio of the
duration of infection, number of human hosts available for
infection, and transmission efﬁciency of each population. We
assumed that there is no difference in transmission efﬁciency
between the sensitive and resistant populations and that the
mutations conferring resistance have negligible impact on
parasite ﬁtness in the absence of drug (i.e., there is no cost of
resistance); therefore the ﬁtness of a partially or fully
resistant parasite relative to the sensitive parasite is the ratio
of their average durations of infection multiplied by the ratio
of the number of hosts available to each to infect. The
assumption of equivalent transmission may not always hold
true, especially where drug resistance appears to correlate
with increased gametocyte production and, possibly, trans-
mission [20,21].
Drug-sensitive parasites (RS) can infect susceptible hosts (S,
Sa), and a proportion (q) of untreated, infected hosts (A, Aa).
Partially resistant parasites (R1) can infect these hosts, and
also those who have been treated and whose drug titer has
declined, but not hosts whose immune responses have been
stimulated by an infection immediately prior to or con-
current with treatment (Figures 1 and 2). For example, they
cannot infect T1 or T19, because these treated hosts are
developing a temporary immune-protected state (P, Pa): their
heightened immune state will temporarily protect them as
the drug protection wanes. Fully resistant parasites (R2) can
infect untreated hosts and any who have been treated,
regardless of the drug titer, but not hosts whose immune
systems are stimulated by a concurrent infection (as
described for R1 above).Thus, the model assumes a degree
of superinfection—a single host can harbor mixtures of
parasites (RS, R1, R2), restricted only by the concentration of
drug in the blood. However, in accord with common practice
[11,22,23], we neglected intrahost dynamics and assumed
independence of genetically distinct coinfecting parasites.
The lifetime of an infection is either the inverse of the rate
at which the parasites are cleared by the immune system (1/g)
or the rate at which they are cleared by the drug (1/a)
following treatment. The average lifetime of an infection in a
host population (‘) is the average of the lifetime of an
infection in nonimmunes and the average lifetime in semi-
immunes weighted by the proportion of infections that occur
in each (Equation 1C). The lifetime of an infection in
nonimmunes (‘NI) is equal to the fraction of infections that
are treated multiplied by the rate of clearance by drug
treatment plus the fraction of infections that are not treated
multiplied by the rate of clearance by immune mechanisms
(Equation 1A). A similar formula (Equation 1B) describes the
lifetime of an infection in semi-immune individuals (‘SI).
‘NI ¼
kp
a
þð 1   kpÞ
  g þ c þ r
ðg þ c þ r þ pðm þ dKÞÞ
2
þ
pðm þ dKÞ
aðg þ c þ r þ pðm þ dKÞÞ
 
ð1AÞ
‘SI ¼
k9p
a
þð 1   k9pÞ
g
ðg þ pd9Þ
2 þ
pd9
aðg þ pd9Þ
"#
ð1BÞ
‘ ¼ fSI ‘SI þð 1   fSIÞ‘NI ð1CÞ
The lifetime of a fully resistant infection is always equal to
the length of time required for the immune system to clear
the infection (1/g).
Figure 2. Schematic Diagram of Model of Malaria Illness and Treatment
Drug use patterns in symptomatic, asymptomatic, and disease-free
individuals.
DOI: 10.1371/journal.pmed.0030141.g002
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IPT and Drug ResistanceThe relative ﬁtness (F) is deﬁned here as the ratio of the
more resistant parasite type over the more sensitive type:
FR2=R1 ¼
½1=g  S þqAþT3þT 9
3 þð1  bÞT2þð1 bÞT 9
2þ SaþqAa
  
‘ SþqAþT 9
3þð1  bÞT 9
2 þSaþ qAa
  
ð2Þ
FR1=RS ¼
ðS þ qA þT 9
3 þð 1   bÞT 9
2 þ Sa þ qAaÞ
ðS þ qA þ Sa þ qAaÞ
ð3Þ
(It is interesting to note that Equation 3 is identical in
structure to Equation 5 in [24], where dr represents the hosts
with residual drug [¼ T39 þ (1   b)T 29], and ds represents the
host with no residual drug [¼ S þ qA þ Sa þ qAa]. Although
these equations were arrived at by different methods, and the
variables S, A, T3, etc...in our model reﬂect changes in the
underlying epidemiology, the qualitative results from the two
approaches are similar.)
The ﬁtness ratio will always be greater than or equal to one.
Weassumedthatthereisnosigniﬁcantcostofresistance.Ifthe
ﬁtness ratio is greater than one, then the more resistant
parasites have a competitive advantage over, or a greater
ﬁtness than, the more sensitive parasites. Assuming that
sensitive parasites are initially established in the host pop-
ulation and a small fraction of resistant parasites arise, the
ﬁtness ratio minus one gives the fraction of spread of the more
resistant parasites per generation. The quantity multiplied by
100 gives the percent of spread per parasite generation.
Spread ¼ð F 1Þ3100 ð4Þ
It has been observed, and is assumed here, that develop-
ment of complete resistance to a drug requires multiple
changes and is therefore stepwise. The appearance of R2
resistant parasites will always be preceded by R1 resistance.
Combining Host and Parasite Model
To compute the ﬁtness of partially and fully resistant
parasites under different scenarios, we solve the equations
describing disease patterns and human dosing for their
equilibrium values and use the values of the state variables (S,
A, D, etc...) in the ﬁtness equations (Equations 2 and 3). High
transmission is deﬁned as one infectious bite per person per
d (annual EIR ¼ 365) and low transmission as 0.01 bites per
person per d (annual EIR ¼ 4). Life expectancy in this model
is assumed to be 50 y; an individual remains nonimmune for
the ﬁrst 1.3 y of life in high transmission and 40 y in low
transmission, after which they become semi-immune. Other
parameter values are listed in Table 2. It is not well
understood how immunity to malaria is acquired or how
long it lasts. For the purposes of our model, however,
sensitivity analysis suggests that the duration of 1/w and 1/w9
have a negligible effect on ﬁtness, and so do not appreciably
affect our results on the relative spread of resistance.
Results
Spread of Resistance in Low- versus High-Transmission
Settings
The ﬁtness of partially resistant parasites (R1) decreases as
transmission intensity (K) increases (Figure 3). However, the
ﬁtness of R2 (fully resistant) parasites per generation initially
increases for low to moderate values of K and then remains
constant for moderate to high values of K.A sK increases, the
fraction of semi-immune individuals in the population
increases because the transition from nonimmune to semi-
immune is proportional to K. As the fraction of the
population that is semi-immune increases, the potential of
partially resistant parasites to spread decreases. However, as
K increases, the number of infections increases, and drug use
Table 2. Parameters, Definitions, and Values
Parameter Description Value
K EIR: infectious bites per person per d 1 per d (high transmission)
0.01 per d (low transmission)
k Fraction of infected semi-immune individuals who become symptomatic 0.5
k9 Fraction of infected immunes who become symptomatic 0.25
c Number of presumptive treatments per person per d 0.016 per d
r
 1 Period of chemoprophylaxis (pharmacokinetic parameters) SP r1
 1 ¼ 15 d [4]
r2
 1 ¼ 37 d
CPG-DDS r1
 1 ¼ 1.2 d [11]
r2
 1 ¼ 4.8 d
a 1 Days to clear an infection after treatment 5 d
g 1 Days to clear an infection by immune mechanisms 33 d
b Fraction of asymptomatic, treated individuals who are immune protected 0.5
w 1 Duration of protection of temporary immunity from infection in semi-immune
individuals (P ! S)
28 d
w9 1 Duration of protection from infection in immune individuals (Pa ! Sa)3 7 0 d
cK Rate of transition from semi-immune to immune state 0.01K
m Rate that asymptomatic infections become symptomatic in nonimmunes 0.01
m9 Rate that asymptomatic infections become symptomatic in semi-immune individuals 0.05
d EIR-dependent rate of transition from asymptomatic to symptomatic infection 0.1
p Probability of receiving treatment for a symptomatic infection 0.8
l Birth and death rate 5.5 3 10
 5 per d
q Fraction of infected individuals who can be superinfected 0.1
r Rate that an infection is cleared without development of immunity 0.01
DOI: 10.1371/journal.pmed.0030141.t002
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IPT and Drug Resistanceincreases, leading to accelerated spread of fully resistant
parasites.
Effect of IPT on Spread of Resistance
To determine how IPT affects the spread of drug
resistance, we evaluated the spread of partially and fully
resistant parasites as a function of c, the number of doses of
drug administered to nonimmune (S, A, P) individuals per
unit time. As expected, the potential spread of resistance
generally increases with dosing (Figure 4). Surprisingly, in
high-transmission areas the spread of full (R2) relative to
partial (R1) resistance was unaffected by changes in IPT
coverage (Figure 4B). Furthermore, although the potential
spread of R1 parasites increased with the rate of IPT dosing,
the increase was much less pronounced in the high-trans-
mission than the low-transmission setting (Figure 4A). In
quantitative terms, relative to RS, R1 parasites have the
potential to increase by 65% each generation when EIR is low
(K¼0.01), but only 10% when EIR is high (K¼1), assuming a
presumptive dosing frequency of about one dose every 60 d (c
¼ 0.016 per d). This difference is inﬂuenced by the larger
proportion of the population residing in the nonimmune
categories in low compared to high transmission (Table 1).
The potential spread of partial resistance per dose of drug
given to nonimmunes is identical in each scenario. In other
words, when presumptive treatment is applied at a uniform
rate across the population, then partial resistance spreads
much more quickly in low-transmission conditions. However,
when presumptive treatment is targeted to a speciﬁc subset of
the nonimmune category such that the number of doses
administered is equivalent, then the potential for partial
resistance to spread is equivalent.
Of much greater concern, R2 parasites have about a 250-
fold advantage over R1 parasites in low-transmission con-
ditions; in high-transmission conditions, R2 parasites have a
300-fold advantage, whatever the value of c. The model also
predicts that under conditions of perfect drug use, that is,
with perfect diagnosis and compliance and no treatment of
uninfected individuals, partial resistance would never spread.
Effect of Drug Elimination Time on Spread of Resistance
Pyrimethamine and sulfadoxine in SP have elimination
half-lives of 116 and 81 h [25], respectively, whereas dapsone
and chlorcycloguanil (the active metabolite of chlorprogua-
nil) in chlorproguanil-dapsone (CPG-DDS or Lapdap) have
much shorter half-lives—about 12 and 20 h, respectively [26].
Because our model incorporates pharmacokinetic properties,
Figure 3. Effect of Increasing the Entomological Inoculation Rate (K) on
the Percent Increase of R1 over RS or R2 over R1 Resistant Parasites
DOI: 10.1371/journal.pmed.0030141.g003
Figure 4. Effect of Increasing IPT Coverage with SP on the Percent
Increase of R1 Relative to RS or R2 Relative to R1 Resistance
Treatment effect is shown for percent increase of (A) R1 relative to RS or
(B) R2 relative to R1 resistance. Increasing treatments of non-diseased
individuals increases the relative spread of R1 and R2 resistance in low-
transmission conditions (A and B) but only R1 resistance in high-
transmission conditions (A).
DOI: 10.1371/journal.pmed.0030141.g004
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IPT and Drug Resistanceit allows us to compare drugs with different clearance times.
Compared to SP, the use of CPG-DDS for IPTi and treatment
decreases the potential spread of partial resistance, in both
low- (Figure 5) and high-transmission conditions. In low-
transmission conditions, CPG-DDS use also reduced the
spread of R2 resistance, but to a lesser extent than for R1
parasites. The difference between SP and CPG-DDS in the
spread of R2 in high-transmission conditions was negligible.
Effect of Treatment
Overall, the spread of partial (R1) resistance is driven by
drug treatment of uninfected, nonimmune individuals
(Figure 4). The dominant factors in the spread of full R2
resistance are the long duration of infections, which are
refractory to drug treatment, and the greater proportion of
human hosts available to R2 phenotypes. As the fraction of
infections that are treated increases, the average lifetime of
drug-susceptible and partially resistant infections decreases,
but the lifetime of fully resistant infections remains the same.
As a result, the ﬁtness of the fully resistant parasites (R2)
relative to the partially resistant parasites increases as the
probability of being treated, p, increases (Figure 6), but the
spread of R1 is largely independent of p. Previous analyses
[11,24], based solely on drug use and drug pharmacokinetic
properties, also identiﬁed the level of overall drug use (in
infected and uninfected individuals) as the crucial factor for
spread of partially resistant parasites, and the proportion of
true infections treated with drug as the driving force for
spread of fully resistant parasites.
IPT in Adults versus Infants
We adjusted the model to reﬂect a drug use scenario in
which semi-immune individuals rather than nonimmunes are
treated presumptively, that is, in which individuals in
categories Sa,P a, and Aa, rather than S, P, and A, are treated
at regular intervals (rate c) with an antimalarial drug under
high-transmission conditions. The potential spread of R1
parasites relative to RS parasites per dose of SP is much
greater when IPT is implemented in infants than when it is
implemented in adults, for example IPT during pregnancy
(Figure 7).
Discussion
By combining a model of host disease and treatment with a
model of relative parasite ﬁtness, we are able to describe the
effects of individual drug treatment on the population
dynamics of malaria parasites. In this composite model, we
incorporated two types of selection of resistant parasites—
within-host selection and transmission selection. Within-host
selection occurs when newly inoculated or surviving resistant
parasites have an advantage over, and out-compete, drug-
sensitive parasites within an individual who has received drug
therapy. This selection is accounted for by incorporating the
pharmacokinetics of drug treatment. Transmission selection
occurs when resistant parasites, present due to in-host
selection, are selectively transmitted and have a greater
number of hosts available for the next generation. This type
of selection is described by the differences in hosts available
for fully resistant, partially resistant, and drug-sensitive
parasites.
Despite the very high usage of chloroquine in high-
transmission areas of Africa, resistance to chloroquine
appeared much later than in lower-transmission areas such
as Southeast Asia [27]. Once resistance appeared, it spread
very quickly. Our model captures this behavior. Partially
resistant parasites spread more slowly when infectious bites
are more frequent. Fully resistant parasites have the potential
to spread much more quickly than partially resistant para-
sites, regardless of the transmission intensity. Assuming that
Figure 6. Effect on the Spread of R1 and R2 Resistance of Increasing the
Proportion of Infected Individuals Who Are Treated
Increasing drug usage in cases of true infection does not affect the
spread of R1 but can select for R2 parasites if they are already present.
DOI: 10.1371/journal.pmed.0030141.g006
Figure 5. Effect of IPT Treatments with Drugs with Different Half-Lives
(CPG-DDS or SP) on the Percent Increase of R1 Relative to RS in a Low-
Transmission Setting
Drugs with shorter half-lives (i.e., CPG-DDS) reduce the window of
selective advantage of more resistant parasites.
DOI: 10.1371/journal.pmed.0030141.g005
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IPT and Drug Resistanceresistance is acquired in a stepwise manner, this is consistent
with the observation that, in regions with high transmission
rates, initial resistance spread more slowly and was detected
later, followed by a rapid spread of highly resistant parasites.
The high levels of acquired antimalarial immunity in sub-
Saharan Africa, relative to lower transmission areas of South
America and Southeast Asia, may be partly responsible for
the delayed appearance of resistance in Africa.
Several recent studies have attempted to deﬁne the
relationship between transmission intensity and spread of
resistance [28–30]. While the relationship is not completely
clear, data collected from several villages in Uganda [28,29]
show that low and high levels of parasite resistance (R1 and
RIII according to the WHO classiﬁcation of parasitological
response [31]) have opposite trends with respect to trans-
mission intensity, consistent with our results. In the same
study, nomeasure of resistance to SP was seen to decrease with
increasing transmission intensity, contrary to our prediction
that spread of partial resistance would decrease with increas-
ing EIR. However, it is not at all clear how to relate the
endpoints measured in the study to the partial and complete
resistance discussed here, or how long ago resistance had been
introduced into each village. The relationship is further
confounded by signiﬁcantly higher antimalarial drug con-
sumption at lower transmission intensities.
In our model, transmission intensity (EIR) inﬂuences the
incidence of disease, and therefore the number of doses of
drug, as well as the development of immunity. These two
factors have opposite effects on the spread of resistance, and
we have captured this in our model. Hastings et al. [11]
predicted that low-transmission conditions would favor the
spread of complete resistance based on the assumption that
the lifetime of an infection would be shorter in semi-immune
individuals and that more infections were likely to be
symptomatic and treated in conditions of low transmission.
We assumed that the frequency of infection and clinical
attack is lower in semi-immune individuals, but the lifetime
of an untreated infection, g, is constant, based on the
observation that semi-immune individuals can harbor long-
lived asymptomatic infections.
Development of partial resistance, or drug tolerance, is a
crucial step in the evolution of drug resistance [32] that has
largely been ignored, particularly in mathematical models of
drug resistance. Our model explicitly considers the inter-
mediate development of drug tolerance on the spread of
drug-resistant malaria. In both low- and high-transmission
settings, as the number of disease-free, nonimmune people
who are treated with drug (IPT) increases, the spread of
partial resistance increases (Figure 4), but the spread of fully
resistant parasites in conditions of high transmission remains
stable. Therefore, if some partial resistance to a particular
drug has already been observed in a high-transmission
setting, IPT is not likely to affect the spread of full resistance,
although the subsequent spread is likely to be rapid. If no
resistance to a drug has been measured, using that drug for
IPT could accelerate the appearance of partial resistance,
which could be followed by explosive spread of full resistance.
Under conditions of low transmission, IPT could increase the
spread of both partially and fully resistant parasites.
The pharmacokinetic properties of a drug should be taken
into consideration when choosing a drug for IPTi. While
drugs with long half-lives are desirable to maximize the
period of protection from each treatment, the same property
will also maximize the window for selection for resistant
phenotypes [4]. The model shows that resistance can spread
more quickly when a drug with a long half-life, such as SP, is
used than when a drug with a shorter half-life such as CPG-
DDS is used, although we do not account for the possibility of
reduced efﬁcacy of IPTi when using a drug with a shorter
protective window. This result is both intuitive and consistent
with previous observations and predictions. For example,
Hastings et al. [11] predicted a relationship between human
drug treatment rate and spread of partially resistant parasites
similar to the results of our model for IPTi. Furthermore,
they predicted that the impact of drug half-life on the
transition from partial to complete resistance is very small
compared to its impact on the transition from sensitive to
partial resistance, similar to what we describe here for high-
transmission conditions. It should be noted, however, that
neither model accounts for the different effects of drugs on
the sexual, transmissible blood forms of the parasite, but
rather assumes that sexual stages are directly proportional to
the asexual forms.
We hypothesized that administering drugs to disease-free
individuals with little or no malaria-speciﬁc immunity, such
as IPT during infancy, would have a greater impact on the
spread of drug resistance than administering drugs to
disease-free adults with some previous exposure and immun-
ity, such as mass drug administration and IPT in pregnancy.
The model predicts that partially resistant parasites have the
potential to spread considerably faster when the same
number of IPT doses is administered to infants (non-
immunes) compared to adults (semi-immune individuals).
We did not explicitly consider presumptive drug use outside
of IPT, and it is not clear whether drug use within IPTi would
be overshadowed by general presumptive treatment. How-
ever, many of these conclusions can be extrapolated to
presumptive treatment, including the prediction that pre-
Figure 7. Effect of IPT in Adults or Infants on the Percent Increase of R1
Relative to RS Parasites
Doses of drug administered to nonimmune infants have a greater impact
on the spread of partial resistance.
DOI: 10.1371/journal.pmed.0030141.g007
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signiﬁcantly to the spread of drug resistance than that in
semi-immune individuals.
These results show the potential effect of IPT on the spread
of drug-resistant parasites in low- and high-transmission
areas. These predictions are not a quantitative evaluation of
the inevitable impact of IPTi, but rather a qualitative
assessment of the relative potential of partially and fully
resistant parasites to establish in a community of available
hosts under different drug use strategies. The mathematical
analysis permits our understanding and assumptions about
the problem to be made explicit and be evaluated. The model
can be used as a tool to determine which are the most critical
questions to be answered before IPTi is implemented on a
broad scale. Although our model captures the factors
inﬂuencing the epidemiology of drug-resistant malaria more
thoroughly than its predecessors, its results, like those of any
model, are sensitive to its underlying structure and should be
used to deﬁne research priorities rather than to accept or
abandon speciﬁc programs.
This analysis highlights the importance of carefully select-
ing the drug to be used in IPTi programs. Cross-sectional
surveys to determine the existing levels of resistance to a
particular drug should be undertaken prior to introducing
IPT programs for infants. Drugs to which little or no
resistance exists are not advisable for IPT in high-trans-
mission areas, but IPTi is not likely to signiﬁcantly impact the
spread of highly resistant parasites in areas where partial
resistance is already established. Drugs with shorter half-lives
should be considered, and the duration of protection from
infection should be weighed against the opportunity for
spread of resistance.
Supporting Information
Text S1. Human Dosing Model Equations
Differential equations for the human dosing model describing the
relationships between infection, disease, treatment, and immunity.
Found at DOI: 10.1371/journal.pmed.0030141.sd001 (37 KB DOC).
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Background. Malaria has been on the rise in the past decade, mainly
because the parasites that cause the disease have become resistant to
the widely used antimalarial drugs. There is no resistance yet to a
promising new class of drugs, called artemisinins. While neither malaria
eradication nor a vaccine seem feasible goals in the next few years,
efforts to combat malaria have recently gained momentum. One strategy
under consideration is to treat people before they get sick. Such
treatment does not prevent infection—which happens through mosqui-
to bites—but it can prevent disease by eliminating the parasites once
they get into the blood. Researchers have some experience with
prevention strategies in pregnant women and infants, who are
particularly vulnerable to malaria. In most studies, the participants
received intermittent preventive treatment (IPT), which means women
received two or three courses of treatment in the second and third
trimesters, and infants got three courses at 2, 3, and 9 months, together
with routine childhood immunizations.
Why Was This Study Done? IPT has been found to reduce the
devastating consequences of malaria during pregnancy and infancy,
provided that the drugs used are still effective (i.e., that the local
parasites have not developed resistance). As a consequence, many
people are calling for IPT to be used more widely, and there is even
discussion of expanding preventive treatment beyond pregnant women
and infants. But experts have warned that widespread treatment of
healthy individuals will increase drug resistance in the parasite, and that
the potential risks and benefits of IPT need to be weighed carefully. One
way to do this is to use predictive disease modeling to estimate the
health benefits as well as the risks—especially drug resistance—under
various scenarios. The authors of this study have focused on estimating
the impact of IPT in adults and infants on parasite drug resistance. It is
important to distinguish infants and adults, because resistance is more
likely to develop in infants whose immune system is immature. In
addition, the blood of infants contains higher levels of parasites, which
means resistant parasites are more likely to be picked up by mosquitoes
and spread to others.
What Did the Researchers Do and Find? They used a mathematical
model that could take into account several different variables. A number
of them influenced the development of resistance, including trans-
mission frequency (i.e., the number of mosquito bites that transmit
malaria parasites per individual per year), the existing level of resistance
to the drug of choice, characteristics of the drug (specifically, how
quickly or slowly it is broken down or removed from the body), and
treatment frequency (i.e., the number of drug courses per year). The
model predicts that partially resistant parasites are more likely to emerge
and spread in low-transmission areas and fully resistant ones in high-
transmission areas. IPT in infants could accelerate the spread of resistant
parasites. This is more likely when drugs that are slowly broken down or
removed are used, because that prolongs the time window during which
parasites are exposed to low levels of drugs that favor selection of
resistant variants.
What Does This Mean? The researchers warn that the use of IPT drugs
to which little or no resistance exists (such as the artemisinins) will likely
accelerate resistance development and should be avoided, especially in
high-transmission areas. For IPT in infants, they suggest that drugs
should be chosen that are broken down or removed quickly and to
which local resistance levels are low. However, like all other modelling
efforts, this one can only suggest likely outcomes and is best used as a
tool to define research priorities and highlight the most critical questions
that must be answered before the widespread implementation of a
particular strategy.
Where Can I Find More Information Online? Pages from the US
Centers for Disease Control and Prevention:
http://www.cdc.gov/malaria/control_prevention/control.htm
WHO pages on malaria, which contain a section on malaria and
pregnancy:
http://www.who.int/topics/malaria/en
MedlinePlus pages on malaria:
http://www.nlm.nih.gov/medlineplus/malaria.html
UNICEF page on malaria with links:
http://www.childinfo.org/eddb/Malaria
IPTi Consortium:
http://www.ipti-malaria.org
PLoS Medicine | www.plosmedicine.org May 2006 | Volume 3 | Issue 5 | e141 0642
IPT and Drug Resistance